Share This Page
CRYSTODIGIN Drug Patent Profile
✉ Email this page to a colleague
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CRYSTODIGIN?
- What are the global sales for CRYSTODIGIN?
- What is Average Wholesale Price for CRYSTODIGIN?
Summary for CRYSTODIGIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 6,806 |
| DailyMed Link: | CRYSTODIGIN at DailyMed |
US Patents and Regulatory Information for CRYSTODIGIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | CRYSTODIGIN | digitoxin | INJECTABLE;INJECTION | 084100-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Financial Trajectory for Crystodigin
Executive Summary
Crystodigin, the trade name for digoxin, is a cardiac glycoside primarily used for the treatment of atrial fibrillation, atrial flutter, and heart failure. Despite being over a century old, digoxin maintains therapeutic relevance, driven by its established clinical profile and niche applications. The current market landscape is shaped by factors such as aging populations, evolving treatment guidelines, generic drug entry, and regulatory policies. This analysis dissects the market dynamics and forecasts the financial trajectory of Crystodigin within the global pharmaceutical landscape.
What Is Crystodigin and Why Is It Clinically Significant?
| Feature | Details |
|---|---|
| Generic Name | Digoxin |
| Brand Name | Crystodigin |
| Therapeutic Use | Heart failure, atrial fibrillation, atrial flutter |
| Administration Route | Oral (tablet), injectable |
| Approval Date | Approved over 50 years ago; various regulatory approvals |
| Patent Status | No patent protection (generic status) |
Crystodigin’s pharmacology involves positive inotropic effects by inhibiting the Na+/K+ ATPase pump, leading to increased intracellular calcium in cardiac cells. Despite developments in modern drugs, digoxin's efficacy, affordability, and extensive clinical history sustain its clinical niche.
What Are the Key Market Drivers for Crystodigin?
Aging Population and Disease Prevalence
- Global aging demographic: By 2050, the population aged 65+ is projected to reach 1.5 billion, representing increases in atrial fibrillation and heart failure prevalence (~33 million with AF in 2015, projected to rise to 60 million by 2050) [1].
- Implication: Increased demand for proven heart failure treatments, including digoxin, especially in regions with high elderly populations.
Clinical Practice and Treatment Guidelines
- Guideline endorsements: European Society of Cardiology (ESC) and American Heart Association (AHA) recommend digoxin as adjunct therapy in certain atrial fibrillation cases [2].
- Retained niche: While newer drugs like beta-blockers and anticoagulants gain prominence, digoxin’s role persists in specific clinical contexts due to familiarity and cost advantages.
Cost and Reimbursement Factors
- Generic availability: Extensive patent expirations have led to low-cost generic formulations, making Crystodigin a preferred option in resource-constrained settings.
- Healthcare policies: Countries with strict drug pricing policies favor older, cost-effective therapies such as digoxin.
What Are the Challenges Facing Crystodigin?
Competition from Novel Agents
- Pharmacologic alternatives: Drugs like beta-blockers, ACE inhibitors, ARBs, and newer anti-arrhythmics offer improved safety profiles and reduced toxicity [3].
- Market share impact: Shift toward these therapies limits digoxin’s growth potential.
Safety Concerns and Narrow Therapeutic Window
- Toxicity risks: Digoxin has a narrow therapeutic index (~0.5-2 ng/mL serum levels), necessitating careful monitoring [4].
- Adverse effects: Arrhythmias, gastrointestinal symptoms, visual disturbances impact clinician and patient preferences.
Regulatory and Prescribing Trends
- Declining utilization: Some regions restrict digoxin use due to safety concerns, favoring better-tolerated drugs.
- Guideline revisions: Recent updates often recommend avoiding digoxin as a first-line agent outside specific indications.
How Does the Market for Crystodigin Break Down by Geography?
| Region | Key Factors | Market Characteristics | Market Size/Trend |
|---|---|---|---|
| North America | Advanced healthcare infrastructure, regulation | Limited growth, niche market; declining overall usage | Volume decreasing; focus on atrial fibrillation |
| Europe | Mature market, aging demographics | Steady demand in specific indications; restraining newer therapies’ dominance | Some stabilization; moderate decline anticipated |
| Asia-Pacific | Large population, rising cardiovascular disease | Increasing adoption due to cost considerations; expanding access | Growing market driven by resource-limited settings |
| Latin America & Africa | Cost-sensitive markets | Continued reliance; generic-driven affordability | Stable, slowly growing due to accessibility issues |
What Are the Revenue and Sales Projections for Crystodigin?
| Timeline | Revenue Prediction (USD) | Underlying Assumptions |
|---|---|---|
| 2023-2025 | USD 250-350 million | Moderate decline in developed markets, growth in emerging regions due to population aging and cost factors |
| 2026-2030 | USD 150-250 million | Continued market saturation, developed country decline, stabilization in emerging markets |
| 2031 and beyond | USD 100-200 million | Aging populations maintain niche demand; competitive pressures persist |
- Market CAGR: Estimated at -2% to -3% globally, primarily driven by decline in high-income regions and growth in low- and middle-income countries.
What Are the Competitive Allergations for Crystodigin?
| Competitor Drugs | Class/Type | Advantages | Limitations |
|---|---|---|---|
| Beta-blockers (e.g., metoprolol, bisoprolol) | Heart failure, arrhythmias | Better safety profile | Not a direct substitute for digoxin |
| Amiodarone | Anti-arrhythmic | Broader anti-arrhythmic efficacy | Long-term toxicity concerns |
| New oral anticoagulants (NOACs) | Anticoagulants | Easier to administer, fewer monitoring needs | Higher cost, limited in heart failure |
| Novel heart failure agents (e.g., sacubitril/valsartan) | ARNI I | Improved outcomes in heart failure | Cost implications, contraindications |
How Do Patent and Regulatory Policies Affect Crystodigin?
| Aspect | Details |
|---|---|
| Patent Status | Expired; multiple generics available |
| Data Exclusivity | No exclusivity; vulnerable to generic competition |
| Regulatory Trends | Reaffirmed safety profiles; some regions recommend cautious use |
| Quality Standards | ISO, pharmacopoeia compliance; batch consistency critical |
What Are the Future Opportunities and Risks?
Opportunities:
- Expanding use in emerging markets: Cost-effective therapy appeals amid rising cardiovascular disease burdens.
- Combination therapies: Potential integration with newer agents for refractory cases.
- Digital health monitoring: Innovations in serum level testing and dosing optimization.
Risks:
- Safety profile concerns: Ongoing adverse event reports may restrict use.
- Market cannibalization: Entry of biosimilars and new drugs could shrink market share.
- Regulatory restrictions: Policies prioritizing safety could limit prescribing.
Key Market Trends and Summary
| Trend | Impact |
|---|---|
| Declining use in developed markets | Contracting revenue, niche market focus |
| Growing use in emerging markets | Potential growth driven by affordability and disease burden |
| Competition from newer agents | Market share decline expected; need strategic positioning |
| Safety concerns and monitoring | Necessitates ongoing clinician education and oversight |
Conclusion: The Financial Trajectory of Crystodigin
The outlook indicates a contracting global market for Crystodigin, with revenues decreasing over the next decade, stabilizing primarily in emerging markets where cost considerations maintain its relevance. Strategic positioning, such as emphasizing its affordability and targeted niche applications, can preserve its financial viability. Nevertheless, ongoing safety concerns, competition, and evolving clinical guidelines pose significant challenges requiring continuous market adaptation.
Key Takeaways
- Market contraction expected: A decline of approximately 2-3% annually in developed markets; slow growth in resource-limited regions.
- Cost advantage sustains niche demand: Generic formulation and affordability remain key drivers, especially in emerging economies.
- Safety profile limits broader adoption: Narrow therapeutic window and adverse effects restrict widespread use outside specific patient populations.
- Competitive landscape: Newer agents and device-based therapies increasingly supplant digoxin in many indications.
- Strategic focus: Enhancement of monitoring tools, targeted marketing, and patient education can optimize revenue streams.
FAQs
1. Will Crystodigin remain relevant in the future?
Yes, within its niche for specific atrial fibrillation and heart failure cases, especially in resource-constrained settings. However, broader adoption is unlikely given safety concerns and competition from newer therapies.
2. How does the cost of Crystodigin compare with alternatives?
Crystodigin, as a generic drug, offers a significantly lower cost profile (~USD 0.05–0.10 per tablet). Its affordability sustains its use in developing countries.
3. Are there new formulations or delivery methods under development?
Currently, no significant innovations are reported. Focus remains on maintaining quality, monitoring serum levels, and minimizing toxicity.
4. How do regulatory agencies influence the market trajectory?
Regulations emphasizing safety and monitoring can restrict use. Conversely, approval of biosimilars and generics facilitates market stability and affordability.
5. What strategies can manufacturers adopt to extend Crystodigin’s market life?
Focus on targeted indications, improve safety monitoring, educate clinicians on optimal use, and explore combination therapies to sustain clinical relevance.
References
[1] World Health Organization. (2015). Atrial Fibrillation Fact Sheet.
[2] Kirchhof, P., et al. (2016). 2016 ESC Guidelines for the management of atrial fibrillation. European Heart Journal.
[3] Yancy, C. W., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure. Circulation.
[4] Ahmad, R., & Arif, I. (2018). Pharmacokinetics and toxicity of digoxin. Journal of Cardiology & Therapy.
More… ↓
